 CAMBRIDGE, Mass., March 09, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. Nasdaq: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it is offering to sell shares of its common stock in an underwritten public offering. 